✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearchIndustryNeurologyMental HealthHemp Clinical Summary The Drug Enforcement Administration has...
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafety Clinical Summary The Drug Enforcement Administration has placed...
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafety Clinical Summary The Drug Enforcement Administration has placed...
CED Regulatory Digest, Since Last Digest, 1 items
Digest covering 1 recent regulatory items.
Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Clinical Summary The U.S. Drug Enforcement Administration has...
CED Regulatory Digest, Since Last Digest, 1 items
Digest covering 1 recent regulatory items.
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyMental Health Clinical Summary The Drug Enforcement Administration has...
Policy Watch: 17 Regulatory Updates — March 14, 2026
Policy WatchMarch 14, 2026. 17 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Regulations.govSchedules...
Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Why This Matters This regulatory action scheduling three new...
Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Clinical Summary The DEA has placed three synthetic opioid...